PRRT Webinar, Oct 20, 2015, Mailman, Wolin, Mittra

Peptide Receptor Radiotherapy for Neuroendocrine Tumors — Free Webinar on October 20, 2015

October 8, 2015

Learn more about Peptide Receptor Radionuclide Therapy (PRRT), how it works, where it is being used, and who is eligible for this treatment. Join Josh Mailman, President of NorCal CarciNET; Dr. Edward M. Wolin, Director of Neuroendocrine and GI Oncology…


“The Waiting Room,” a Lung Carcinoid Survivor’s Story

September 26, 2015

“We are survivors here, in the waiting room.” Lisa Pawlak, a lung carcinoid survivor, shares her inspiring story in the September/October 2015 issue of Coping with Cancer Magazine.  Read Lisa’s article here.…

Smart Patient quote_2

Smart Patients Carcinoid and Neuroendocrine Tumor Community — Join the Conversation!

September 4, 2015

The Carcinoid Cancer Foundation is excited to announce a new online community for carcinoid and neuroendocrine tumor (NET) patients, their families and friends. We are partnering with Smart Patients to build this community and hope that combining …

Big Apple NETs_0

September Luncheon with the Experts in NYC for Carcinoid and Neuroendocrine Tumor Patients

August 16, 2015

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs

Survey, online, feedback

Help Us to Help You: New Survey for the Carcinoid and Neuroendocrine Tumor Community

August 13, 2015

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner,Ipsen, to better understand…


Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

CME, Emerging Therapies for Neuroendocrine Tumors_New Perspectives for Oncology Nurses

Educational Program for Oncology Nurses on Emerging Therapies for Neuroendocrine Tumors

August 2, 2015

“Emerging Therapies for Neuroendocrine Tumors: New Perspectives for Oncology Nurses,” is an educational program jointly provided by the Postgraduate Institute for Medicine and the Center of Excellence Media, LLC. The program, offered through June

Warner Advocacy Award

Call for Nominations: 6th Annual Warner Advocacy Award

July 30, 2015

Do you know someone who is a passionate advocate for patients with neuroendocrine tumors (NETs)? Novartis Oncology and The NET Alliance are searching for an outstanding NET patient advocate to recognize and honor with the 6th Annual Warner Advocacy


Surviving Carcinoid Cancer for More Than 3 Decades

July 14, 2015

Marilyn Thurston of Colorado may be the longest-surviving carcinoid patient in the United States and possibly the world, having been diagnosed over 30 years ago.  Her physician, Dr. Nicholas DiBella, created a special pin recognizing her tenacity.…

Michael Farris, Fox 4 TV coverage

Denied: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 10, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…